Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria~* Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at Baseline~Exclusion Criteria:~* Secondary or primary progressive multiple sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ozanimod 0.5 mg (Type: EXPERIMENTAL): Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 0.5 mg weekly for another 96 weeks.
- Ozanimod 1 mg (Type: EXPERIMENTAL): Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 1 mg weekly for another 96 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to ozanimod oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and were randomized to receive ozanimod 0.5 mg or 1 mg weekly for 96 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).